Business Wire

May 09, 2005 02:35 PM US Eastern Timezone

Business Editors/Health/Medical Writers

American College of Obstetricians and Gynecologists Conference

Booth No. 3233

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4884068

CHARLESTON, S.C.--(BUSINESS WIRE)--May 9, 2005--QualiLife Pharmaceuticals, Inc., a science-driven company focused on developing and commercializing meaningful consumer products for the sexual health marketplace, will exhibit Zestra(TM) at the upcoming American College of Obstetricians and Gynecologists Conference ("ACOG"), in San Francisco May 7-11, 2005. Non-prescription Zestra(TM) is the only clinically proven topical product available for women who experience sexual difficulties.

Zestra(TM) Feminine Arousal Fluid (U.S. Patent 6,737,084) is the only product of its kind whose clinical study results are published in peer-reviewed medical journals. No other product is proven to be more effective for increasing female sexual arousal, pleasure and satisfaction. Zestra's(TM) all-natural ingredients are not found in any other women's sexual product. Zestra(TM) is topically applied, hormone-free and is not a drug.

"We are honored to be a part of the American College of Obstetricians and Gynecologists Conference," said pharmacist Martin Crosby, President & Chief Scientific Officer of QualiLife Pharmaceuticals, Inc. "QualiLife Pharmaceuticals is dedicated to addressing women's sexual wellness needs. Our Company's goal is to help satisfy those unmet needs with pioneering, effective consumer products that can improve the quality of life for millions of women."

In March 2005, Obstetrical and Gynecological Survey published a Continuing Medical Education (CME) Review Article that acknowledges the benefits of Zestra(TM) for both arousal and orgasmic difficulties. The objective of the CME Review Article titled "Female Sexual Dysfunction: Principles of Therapy" is to provide the most current clinical information available to Obstetricians and Gynecologists on the topic of female sexual dysfunction and the principles of diagnosis and therapy.

The CME Review Article cites a clinical trial conducted by QualiLife Pharmaceuticals titled "Randomized Placebo-Controlled Double Blind, Crossover Design Trial of the Efficacy and Safety of Zestra for Women in Women With, and Without Female Sexual Arousal Disorder (FSAD)." The study of 20 women showed improvement in level of desire, arousal, sensation, pleasure and ability to have orgasms in both normal and FSAD patients using Zestra(TM), as compared with placebo. Zestra(TM) is the only product listed in the CME Review Article that has published clinical study results and no known negative effects.

ACOG conference attendees are invited to visit with QualiLife Pharmaceuticals' at booth number 3233 to learn more about Zestra(TM) and meet the product's inventor, pharmaceutical researcher and sexual medicine expert Martin G. Crosby

Antidepressants & Sex

In a landmark clinical study, Zestra(TM) eliminated the undesirable sexual side effects that often stem from antidepressant use. According to David M. Ferguson, Ph.D., M.D., a widely-recognized sexual medicine expert and pharmaceutical industry consultant, "Only Zestra(TM) is clinically proven in a double blind, placebo-controlled crossover clinical trial to increase female sexual pleasure in normal women, women with arousal difficulties and in women suffering sexual side effects from antidepressant medications."

About Patented Zestra(TM) Feminine Arousal Fluid

Zestra(TM) for Women is the patented topically applied feminine arousal fluid that was scientifically formulated by pharmacists and sexual health experts to increase female sexual pleasure. Ingredients: PA-Free Borage Seed Oil, Evening Primrose Oil, Angelica Extract, Coleus Extract, Vitamin C, Vitamin E and natural fragrances.

In published clinical studies conducted by independent sexual medicine experts, Zestra(TM) improved level of desire, satisfaction and enhancement of sexual experiences in women. More information is available at www.zestraforwomen.com.

About QualiLife Pharmaceuticals, Inc.

QualiLife Pharmaceuticals, Inc. is a science-driven company focused on developing and commercializing meaningful consumer products for the sexual health marketplace. The Company combines its expertise in pharmacology, neurology, transdermal delivery and medicinal chemistry together with identification of "bio-active principles" in plants to develop highly innovative consumer products with significant commercial potential. The Company applies its integrated approach to specific target areas where it has substantial expertise. QualiLife Pharmaceuticals' believes this R&D strategy increases the chances of successfully developing effective and widely embraced consumer products. These target areas primarily involve female and male sexual health and other natural products that deliver substantial quality of life enhancements.

Where to Find Zestra(TM)

Zestra(TM) is now available in more than 4,700 Walgreens pharmacies across the country, and more than 250 Duane Reade drugstores in the metropolitan New York City area. Zestra(TM) is expected to be available on the shelves of more than 15,000 pharmacy chains stores nationwide by mid-summer 2005.

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4884068

CORPORATE CONTACT:
Martin G. Crosby
Chairman & Chief Science Officer
Zestra Laboratories, Inc.
4055 Faber Place Drive, Suite 300
Charleston, SC 29405
843.402.0901 (phone)
843.402.0919 (fax)
www.zestraforwomen.com

Source: Zestra Laboratories, Inc.

Download the PDF version.